摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-thiomorpholinophenyl)ethanone | 166438-89-7

中文名称
——
中文别名
——
英文名称
1-(4-thiomorpholinophenyl)ethanone
英文别名
1-[4-(4-Thiomorpholinyl)phenyl]ethanone;1-(4-thiomorpholin-4-ylphenyl)ethanone
1-(4-thiomorpholinophenyl)ethanone化学式
CAS
166438-89-7
化学式
C12H15NOS
mdl
——
分子量
221.323
InChiKey
BAVIDNPPCSYIIP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    406.2±40.0 °C(Predicted)
  • 密度:
    1.148±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    45.6
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    1-(4-thiomorpholinophenyl)ethanonepotassium carbonate 作用下, 以 1,4-二氧六环乙醚丁酮 为溶剂, 反应 10.5h, 生成 2-phenoxy-1-(4-thiomorpholinophenyl)ethan-1-one
    参考文献:
    名称:
    噻唑烷酮类药物的结构设计,合成及构效关系与克氏锥虫活性增强的关系
    摘要:
    查加斯病的药理治疗是基于苯并硝唑,当在慢性感染阶段给药时,苯并硝唑的疗效较差。因此,需要开发新的治疗选择。这项研究报告了新型抗克鲁斯锥虫噻唑烷酮(4 a – p)的结构设计和合成。(2- [2-苯氧基-1-(4-溴苯基)亚乙基)hydr]] 5-乙基噻唑烷-1-酮(4小时)和(2- [2-苯氧基-1-(4-苯基苯基)亚乙基] hydr] [ ] -5- ethylthiazolidin -4-酮(4升)是最有效的化合物,从而减少epimastigote增殖并且是毒性trypomastigotes在低于10浓度μ中号,尽管它们在200μM的浓度下都没有表现出宿主细胞毒性。噻唑烷酮4 h能够减轻小鼠体内的体外寄生虫负担和血液寄生虫血症,效力与苯硝唑相似。更重要的是,在不表现出小鼠毒性的情况下实现了克氏锥虫感染的减少。关于作用的分子机制,这些噻唑烷酮不抑制克鲁萨因活性,克鲁萨因是主要的锥虫蛋白酶
    DOI:
    10.1002/cmdc.201300354
  • 作为产物:
    参考文献:
    名称:
    Isoxazolinone antibacterial agents
    摘要:
    这项发明描述了具有抗菌活性并可用于治疗细菌性疾病的异噁唑烷酮化合物。更具体地,提供了具有以下结构式的异噁唑烷酮:
    公开号:
    US06420349B1
点击查看最新优质反应信息

文献信息

  • Novel isoxazolinone antibacterial agents
    申请人:——
    公开号:US20020094984A1
    公开(公告)日:2002-07-18
    This invention describes isoxazolinone derivatives which possess antibacterial activity and are useful in the treatment of bacterial diseases. More particularly, new isoxazolinones are provided having the general formula 1 wherein A and R 1 are as described in the specification.
    本发明描述了一种具有抗菌活性的异氧嗪酮衍生物,可用于治疗细菌性疾病。更具体地,提供了新的异氧嗪酮衍生物,其具有一般式1,其中A和R1如规范所述。
  • Structure–activity relationship study of a novel necroptosis inhibitor, necrostatin-7
    作者:Weihong Zheng、Alexei Degterev、Emily Hsu、Junying Yuan、Chengye Yuan
    DOI:10.1016/j.bmcl.2008.08.058
    日期:2008.9
    Necroptosis is a regulated caspase-independent cell death mechanism characterized by morphological features resembling non-regulated necrosis. Necrotatin-7 (Nec-7), a novel potent small-molecule inhibitor of necroptosis, is structurally distinct from previously described necrostatins (Nec-1, Nec-3, Nec-4 and Nec-5). Here, we describe a series of structural modi. cations and the structure-activity relationship (SAR) of the Nec-7 series for inhibiting necroptosis. (C) 2008 Elsevier Ltd. All rights reserved.
  • Design, Synthesis and Antitubercular Activity of Novel Isoniazid‑Cyclic‑Amine‑Azachalcones Hybrids
    作者:Jefferson Oliveira、Cristiane Shiguemoto、Amarith das Neves、Flora Moreira、Giovana Gomes、Renata Perdomo、Sandro Barbosa、Palimécio Guerrero Jr.、Júlio Croda、Adriano Baroni
    DOI:10.21577/0103-5053.20200013
    日期:——
    In this work, it is described the design of twenty-four heterocyclic amine-azachalcones compounds through molecular hybridization of chalcone scaffold and fragments of isoniazid, fluoroquinolones, and linezolid with antituberculosis potential. The new compounds were synthesized via Claisen-Schmidt condensation, providing yields of 36-95%. Fifteen compounds showed antituberculosis activity against Mycobacterium tuberculosis H37Rv strain. Two amine-azachalcones 15 and 17 showed relevant biological activity with minimum inhibitory concentration (MIC) values of 6.62 and 4.85 mu M, respectively. Compound 12 showed the best profile of antitubercular activity with MIC = 9.54 mu M and selectivity index (SI) = 9.33. It was found that morpholine group is important to increase potency of antimycobacterial activity but also to add some toxicity to the chalcone molecular framework. The results described herein would be a guide in the designing of novel and optimized antitubercular derivatives based on the chalcone scaffold.
  • NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:EP1107756A1
    公开(公告)日:2001-06-20
  • EP1107756A4
    申请人:——
    公开号:EP1107756A4
    公开(公告)日:2003-02-26
查看更多